Financials data is unavailable for this security.
View more
Year on year VIVA Biotech Holdings had revenues fall -9.42% from 2.38bn to 2.16bn, though the company grew net income from a loss of 528.48m to a smaller loss of 116.11m.
| Gross margin | 33.66% |
|---|---|
| Net profit margin | 1.54% |
| Operating margin | 1.93% |
| Return on assets | 0.40% |
|---|---|
| Return on equity | -0.01% |
| Return on investment | 0.56% |
More ▼
Cash flow in CNYView more
In 2023, VIVA Biotech Holdings increased its cash reserves by 52.72%, or 357.75m. Cash Flow from Investing totalled 439.17m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 383.41m in cash from operations while cash used for financing totalled 429.50m.
| Cash flow per share | 0.1248 |
|---|---|
| Price/Cash flow per share | 5.14 |
| Book value per share | 1.95 |
|---|---|
| Tangible book value per share | 0.6366 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.65 |
|---|---|
| Quick ratio | 1.46 |
| Total debt/total equity | 0.4067 |
|---|---|
| Total debt/total capital | 0.2884 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 78.31%.
| Div yield(5 year avg) | 0.15% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | -- |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 97.78 |
More ▼
